AbbVie Inc. Common Stock Approved for Listing on NYSE Euronext Paris

PR Newswire/Les Echos/ 
AbbVie Inc. Common Stock Approved for Listing on NYSE Euronext Paris 
ABBOTT PARK, Ill., Dec. 17, 2012 -- Abbott (NYSE: ABT) announced today that the
French Autorité des marchés financiers ("AMF") has approved the prospectus
filed by AbbVie Inc., its research-based pharmaceuticals business, for 
admission of AbbVie Inc.'s common stock to listing and trading on the 
Professional Segment of NYSE Euronext Paris ("Euronext"), and has granted visa 
number 12-599, dated Dec. 14, 2012, on the prospectus (the "Prospectus"). The 
attention of investors is drawn to the risk factors described in the 
Prospectus. 
On Nov. 28, 2012, Abbott's board of directors approved the separation of 
AbbVie, and declared a special dividend distribution of one share of AbbVie 
common stock for each Abbott common share outstanding as of the close of 
business on Dec. 12, 2012, the record date for the distribution. Abbott expects
the special dividend of AbbVie stock will be distributed on Jan. 1, 2013. 
On Dec. 14, 2012, Euronext approved AbbVie Inc.'s application for listing and
trading of its Common Stock on Euronext. "As-if-and-when-issued" trading of
AbbVie common stock is expected to begin on Euronext on Dec. 20, 2012. AbbVie
Inc. common stock will trade on Euronext under the symbol "ABBV" and be
denominated in Euros. 
"As-if-and-when-issued" trading of AbbVie common stock will continue on 
Euronext until Abbott pays the special dividend distribution of AbbVie common 
stock on Jan. 1, 2013. AbbVie "as-if-and-when-issued" trades on Euronext will 
settle after Jan. 1, 2013, with shares of AbbVie as a standalone company.
Abb Vie's common stock is listed on the New York Stock Exchange, under the
symbol "ABBV.WI" for "when issued" trading until Dec. 31, 2012, and "ABBV" for
"regular-way" trading beginning Jan. 2, 2013. AbbVie also intends to list its
common stock on the Chicago Stock Exchange and the SIX Swiss Exchange. 
Copies of the Prospectus may be obtained free of charge from AbbVie Inc. at 
1 North Waukegan Road, North Chicago, Illinois 60064, U.S.A., from its paying
agent, BNP Paribas Securities Services (Postal address: 3, rue d'Antin, 75002,
France), and on the website of the AMF (www.amf-france.org). Until Dec. 31,
2012, the Prospectus will be available on the website of Abbott Laboratories
(www.abbott.com). Beginning Jan. 1, 2013, AbbVie Inc. will maintain an Internet
site at www.abbvie.com, where the Prospectus will be available. 
About Abbott 
Abbott is a global, broad-based health care company devoted to the discovery,
development, manufacture and marketing of pharmaceuticals and medical products,
including nutritionals, devices and diagnostics. The company employs
approximately 91,000 people and markets its products in more than 130
countries. 
Abbott's news releases and other information are available on the company's Web
site at www.abbott.com. 
         - Private Securities Litigation Reform Act of 1995 - 
            A Caution Concerning Forward-Looking Statements 
Some statements in this news release may be forward-looking statements for
purposes of the U. S. Private Securities Litigation Reform Act of 1995,
including the planned separation of the research-based pharmaceutical company
from the diversified medical products company. Abbott undertakes no obligation
to release publicly any revisions to forward-looking statements as a result of
subsequent events or developments, except as required by law.
 

SOURCE Abbott 
CONTACT: Media, Adelle Infante, (847) 938-8745, or Financial, Larry Peepo, 
(847) 935-6722 
                  
The content and accuracy of news releases published on this site and/or 
distributed by PR Newswire or its partners are the sole responsibility of the 
originating company or organisation. Whilst every effort is made to ensure the 
accuracy of our services, such releases are not actively monitored or reviewed 
by PR Newswire or its partners and under no circumstances shall PR Newswire or 
its partners be liable for any loss or damage resulting from the use of such 
information. All information should be checked prior to publication. 
-0- Dec/18/2012 17:14 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.